1029714-88-2 Usage
General Description
2-Fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoic acid is a complex and highly specific chemical compound with potential pharmaceutical applications. The compound contains a benzene ring with a fluorine and a carboxylic acid functional group, as well as a quinoline and imidazole subunit. This combination of chemical features suggests that it may have the ability to modulate biological pathways or interact with specific proteins. It is possible that this compound could be studied for its potential to treat certain diseases or conditions, or to serve as a chemical tool in biological research. Further investigation into its properties and potential uses in the field of pharmaceuticals or biochemistry is warranted.
Check Digit Verification of cas no
The CAS Registry Mumber 1029714-88-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,9,7,1 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1029714-88:
(9*1)+(8*0)+(7*2)+(6*9)+(5*7)+(4*1)+(3*4)+(2*8)+(1*8)=152
152 % 10 = 2
So 1029714-88-2 is a valid CAS Registry Number.
1029714-88-2Relevant articles and documents
Preparation method of capmatinib
-
Paragraph 0040-0042, (2020/11/09)
The invention provides a preparation method of capmatinib. The inventor carries out wide and deep research, massive screening and testing. A compound represented by a formula III is adopted as the rawmaterial for hydrolysis reaction and methylation reaction to obtain a formula I compound, namely capmatinib. The method is mild in reaction condition, environment-friendly, low in energy consumption,good in product purity and high in yield, and is suitable for industrial large-scale production.
Deuterated Capmatinib compounds and uses thereof
-
Paragraph 0052; 0063-0064, (2019/12/25)
The invention discloses deuterated Capmatinib compounds and uses thereof, in particular to compounds represented by formula (I) or optical isomers, pharmaceutically acceptable salts, hydrate or solvate thereof, wherein R1-R16 is independently selected fro
IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
-
Page/Page column 45, (2008/12/05)
-
